skip to Main Content

Moffitt’s Basal-Like Gene Signature Associated With Poor Survival in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The Moffitt gene sets of locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) identified a poor prognostic group, according to a study presented at the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts.

Though RNA signatures have been studied in PDAC, a clinically meaningful tool has not yet been developed. The purpose of the COMPASS trial was to use molecular characterization of patients with PDAC prior to treatment to identify predictive and prognostic biomarkers. Read more . . . 

Back To Top